Latest Breaking News On - Annual european hematology association - Page 1 : comparemela.com

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential (NASDAQ:VRTX)

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential (NASDAQ:VRTX)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United kingdomSaudi arabiaUnited statesSam kulkarniReshma kewalramaniEmmanuelle charpentierJennifer doudnaPfizer incIntellia therapeutics incVertex pharmaceuticals incorporatedNational football leagueEuropean hematology associationBeam therapeutics incEditas medicine incModerna incVerve therapeutics inc

Vertex Pharmaceuticals Incorporated: Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

Both trials met the primary and key secondary endpoints at the pre-specified interim analysis - Data continue to demonstrate transformative and durable benefit - Safety profile consistent with busulfan

City ofUnited kingdomSan franciscoUnited statesMecklenburg vorpommernSusie lisaRachel eidesCarmen bozicMiroslava minkovaExagamglogene autotemcelSusan kimManisha paiStefan klotterHeather nicholsFranco locatelliEuropean hematology association

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

- Both trials met the primary and key secondary endpoints at the pre-specified interim analysis - - Data continue to demonstrate transformative and durable benefit - - Safety profile consistent. | June 9, 2023

United statesCity ofUnited kingdomSan franciscoFranco locatelliExagamglogene autotemcelCarmen bozicAmerican society of hematology annual congressEuropean hematology associationDepartment of pediatric hematologyVertex pharmaceuticalsEuropean commissionViacyte incEuropean medicines agencySapienza university of romeCompanies to work

Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress

Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hendrik nogaiRaajit rampalCorporatenatalia baranowska ryvuJohn fraunces lifesciEuropean hematology associationMemorial sloan kettering cancer centerMenarini groupWarsaw stock exchangeClinical dataOngoing phaseDose escalation studyFavorable safetyPromising signsHighlight synergistic effectsAcute myeloid leukemiaHigh risk myelodysplastic syndromes

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Pawel przewiezlikowskiHendrik nogaiPartner menarini groupMenarini groupEuropean hematology associationWarsaw stock exchangeAnnual european hematology associationChief medical officerDose escalation studyEfficacy data updateClinical signsMutation positiveFirst in class dualMutated acute myeloid leukemiaRyvu therapeutics